



Clearly for her

Clearer skin that lasts, so that she can plan ahead

PsO Psoriasis (PsO)
Adult patients with moderate to severe plaque psoriasis.




cimzia[®]
(certolizumab pegol)



CIMZIA[®] dosing for patients with moderate to severe plaque psoriasis

Recommended dose is 400 mg every 2 weeks

| Week 0 | Every 2 Weeks |
|------------------------------|------------------------------|
| 2 injections (2 x 200 mg) | 2 injections (2 x 200 mg) |
| 400 mg | 400 mg |


Each prefilled syringe and autoinjector pen contains 200 mg per 1 mL

UCBCares[™]
Supporting you on your treatment journey.

offers flexible support for your patients' needs, including:

- ✓ Reimbursement navigation and financial assistance
- ✓ Educational support
- ✓ Injection training
- ✓ Pharmacy services
- ✓ Ongoing adherence support

* A dose of 400 mg initially (Week 0) and at Weeks 2 and 4 followed by 200 mg every 2 weeks may be considered.



Administration designed with patients in mind

CIMZIA® gives your patients the option to choose their preferred administration method

CIMZIA® prefilled syringe

Large thumb pad

makes it easy for patients to push the plunger

Over-sized plunger rod

provides stability

Oval syringe barrel

helps prevent spinning between fingers

Rounded finger loop

enables easy removal of needle cap



Non-slip finger grip

allows patients to hold the syringe steady using various grip positions



CIMZIA® autoinjector pen

Button-free injection

First click

signals injection initiation

Second click

signals injection completion (after 15 seconds)

Orange band

indicates device is ready to use



Wide, latex-free, non-slip grip

Viewing window

enables patients to monitor medication administration (turns orange upon injection completion)

Retractable needle

locks and is hidden after injection



Each prefilled syringe and autoinjector pen contains 200 mg per 1 mL

Pre-filled syringe designed for comfort and control in partnership with
Pen designed for comfort and ease-of-use in partnership with



UCBCares™: Your patient's treatment journey, simplified. Call us at 1-800-908-5555.

Indications and Clinical Use:

Geriatrics (≥ 65 years of age): Specific clinical studies have not been performed in elderly subjects.

Pediatrics (< 18 years of age): Safety and efficacy of CIMZIA® in pediatric patients have not been established.

Contraindications:

- Hypersensitivity to CIMZIA® (certolizumab pegol) or any of its components
- Active tuberculosis or other severe infections such as sepsis, abscesses and opportunistic infections
- Moderate to severe heart failure (NYHA Class III/IV)

Most Serious Warnings and Precautions:

Serious infections: serious infections, sepsis, tuberculosis (including miliary disseminated and extrapulmonary disease), invasive fungal infections (such as histoplasmosis) and other opportunistic infections, some of which have been fatal, have been reported in patients receiving TNF blocking agents including CIMZIA®. Many of these occurred in patients on concomitant immunosuppressive therapy that, in addition to their underlying disease, could predispose them to infections. CIMZIA® should not be given to patients with a clinically important infection including chronic or localized infections. Physicians should exercise caution when considering the use of CIMZIA® in patients with a history of recurring infection. Patients should be monitored for signs and symptoms of infection while on and after treatment with CIMZIA®.

Any new infection that develops while on CIMZIA®, or after recent treatment, should be closely monitored. CIMZIA® should be discontinued if a patient develops a serious infection.

Malignancy: lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA® is a member. CIMZIA® is not indicated for use in pediatric patients.

Other Relevant Warnings and Precautions:

- Worsening congestive heart failure and new onset CHF
- Hepatitis B virus reactivation
- Hematological reactions: pancytopenia (including aplastic anemia); cytopenia (leukopenia, pancytopenia, thrombocytopenia)
- Neurologic reactions (new onset or exacerbation of CNS demyelinating disease, including multiple sclerosis and PNS demyelinating disease, including Guillain-Barré syndrome)
- Use in combination with other biologic medicines is not recommended
- Use caution when switching between biologic DMARDs and in surgery
- A patient who requires surgery while on CIMZIA® should be closely monitored for infections, and appropriate actions should be taken
- Hypersensitivity
- Latex sensitivity
- Formation of autoantibodies
- Administration of live or live-attenuated vaccines is not recommended
- Use in patients with severe immunosuppression
- May cause erroneously elevated activated partial thromboplastin time (aPTT) assay results in patients without coagulation abnormalities
- Use in women of childbearing potential, pregnant women and nursing women

For more information:

Consult the product monograph at <https://www.ucb-canada.ca/en/Our-Medicines/overview> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available through Medical Information Services at 1-866-709-8444.

Reference: CIMZIA® Product Monograph, UCB Canada Inc., December 2018.



OXO Good Grips and the associated logos are registered trademarks of Helen of Troy Limited and are used under license. The Arthritis Society "Ease of Use" logo is used under license from The Arthritis Society. CIMZIA, UCB, the UCB logo and UCBCares are trademarks of the UCB group of companies. © 2022 UCB Canada Inc. All rights reserved.



CRA-22-037E